Enlivex Therapeutics Ltd

ENLV14 Dec 2024
Healthcare
$1.22
-0.01 (-0.83%)
Lowest Today
$1.15
Highest Today
$1.23
Today’s Open
$1.22
Prev. Close
$1.21
52 Week High
$4.59
52 Week Low
$0.81
To Invest in Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd

Healthcare
ENLV14 Dec 2024
-0.01 (-0.83%)
1M
3M
6M
1Y
5Y
Low
$1.15
Day’s Range
High
$1.23
1.15
52 Week Low
$0.81
52-Week Range
52 Week High
$4.59
0.81
1 Day
-
1 Week
-5.6%
1 month return
+9.25%
3 month return
-24.84%
6 month return
-19.17%
1 Year return
-16.31%
3 Years return
-80.65%
5 Years return
-86.84%
10 Years return
-
Institutional Holdings
Armistice Capital, LLC
9.73
Morgan Stanley - Brokerage Accounts
1.12
Renaissance Technologies Corp
0.34
Dolphin 90/10 IL
0.2
MTF TR TA-Growth
0.17
Sigma Investment Counselors Inc
0.14
XTX Topco Ltd
0.1

Market Status

Fundamentals
Market Cap
27.71 mln
PB Ratio
1.04
PE Ratio
0
Enterprise Value
3.97 mln
Total Assets
36.83 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Organisation
Enlivex Therapeutics Ltd
Employees
0
Industry
Biotechnology
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step